NCT03934684 2025-08-06
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma
Amgen
Phase 4 Completed
Amgen
Emory University
Novartis
Columbia University
Dana-Farber Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
Novartis